UK-based Oxford Genetics, which specialises in providing bio-engineering services, has raised £7.5 million. The round was led by existing investor Mercia Technologies PLC and Invesco Perpetual.
Oxford Genetics offers a range of services related to synthetic biology and engineering, such as DNA design, protein and anti-body engineering, viral engineering, and bio-production of cell lines for a variety of applications including cancer therapies.
The new investment will fund a new office in Boston, and a major extension of its UK facility at the Oxford Science Park.
“The future is looking genuinely exciting for Oxford Genetics," said Ryan Cawood, the company's CEO, in a statement. "Over the last few years there has been a huge number of promising steps in the complex biologics field towards delivering real patient benefits, and Oxford Genetics is pleased to be working with so many of the companies tackling some of medicine's most significant challenges. This latest investment will allow us to further strengthen our solid foundations of innovative technologies and deliver on our mission to improve the overall efficiency of the biotherapeutic industry through the application of synthetic biology.”
The company says it has experienced substantial growth in the past year, with an increasing number of clients and greater market momentum in the areas of cell and gene therapy.
Read more: Oxford Genetics (Press release)